Clinician's Roundtable

Guest: Wayne Kuang, MD The 2025 American Urology Association Annual Meeting promises to unite the global urology community across six continents around transformative education, game-changing trials, and a renewed focus on patient-centered care. Dr. Wayne Kuang, CEO of MD for Men in Albuquerque and Founder of the ManVsProstate campaign, dives into what makes this year’s conference truly exciting.

Guest: Wayne Kuang, MD Holistic health, fearless thinking, and proactive choices can be transformative in urological health. Dr. Wayne Kuang, CEO of MD for Men in Albuquerque and Founder of the ManVsProstate campaign, explores how we can create a future that works for everyone in the realm of urology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Dougherty, MD Rural populations face unique challenges in accessing colorectal cancer screening, leaving many patients in these communities unscreened. However, mailed fecal immunochemical testing (FIT) may help address these barriers and improve adherence. Joining Dr. Peter Buch to discuss the benefits and limitations associated with FIT and its potential impact on the colorectal cancer screening landscape is Dr. Michael Dougherty. Dr. Dougherty is an Adjunct Assistant Professor in the Division of Gastroenterology and Hepatology at the University of North Carolina School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: A. Mark Fendrick, MD Colorectal cancer screening saves lives—but how do common methods like colonoscopy and non-invasive screening methods compare in their environmental effects? With the healthcare sector being responsible for over four percent of the global carbon footprint, researchers are looking into more environmentally friendly options that can still provide optimal outcomes for patients. Dr. Peter Buch sits down with Dr. Mark Fendrick to examine the carbon footprint of available colorectal cancer screening strategies and explore how a shift to noninvasive options could offer promising clinical and environmental impacts. Dr. Fendrick is a Professor of Internal Medicine and Health Management and Policy at the University of Michigan.

Host: Brian P. McDonough, MD, FAAFP Guest: Sheila Reddy, MD Guest: Carol M. Antequera, DMSc, PA-C When treating patients with irritable bowel syndrome with diarrhea (IBS-D), primary care providers have a variety of pharmacologic or behavioral options to choose from. Creating a personalized, integrative care plan can help address symptoms and maintain patient well-being. Join Dr. Brian McDonough, Dr. Sheila Reddy, and Ms. Carol Antequera as they share their perspectives on individualizing IBS-D care and facilitating communication with patients. Dr. Reddy is a board-certified gastroenterologist at Austin Gastroenterology in Texas, and Ms. Antequera is a physician assistant specializing in gastroenterology at the University of Miami Health System in Florida. Salix Pharmaceuticals400 Somerset Corporate Blvd.Bridgewater, NJ 08807© 2025 Salix Pharmaceuticals or its affiliates. MED-US-NPR-0060

Guest: Bilal Chughtai, MD Advancements in diagnostics and treatment have led to enhanced personalized care for patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB). Minimally invasive treatments have the potential to replace medication for BPH, while a greater focus on bladder health can help differentiate the two conditions and improve outcomes. Learn how these advances are shaping BPH and OAB management with Dr. Bilal Chughtai, Chief of Urology at Plainview Hospital and Associate Professor of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

Guest: Atul A. Deodhar, MD, MRCP Based on data from 25 studies, ixekizumab has a lower risk of common adverse events like depression, cardiovascular events, cancer, and uveitis that are often seen with other treatments for psoriasis, psoriatic arthritis, and axial spondyloarthritis. Here to share the safety findings on ixekizumab is Dr. Atul Deodhar, Professor of Medicine and the Medical Director of Rheumatology Clinics at Oregon Health & Science University

Guest: Vernon K. Sondak, MD Melanoma treatment has undergone a rapid evolution. Immunotherapy has doubled survival rates, and timing the use of these drugs around surgery has shown to be even more effective. Dr. Vernon Sondak explores how the fight against melanoma is stronger than ever with new therapeutic combinations and evolving treatment strategies. Dr. Sondak is the Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida.

Guest: Katrina Abuabara, MD, FAAD Phototherapy, biologics, and JAK inhibitors can all play a role in atopic dermatitis treatment, but it’s essential to consider patient-specific factors before choosing one of these options. Dr. Katrina Abuabara, Associate Professor of Dermatology at the University of California, San Francisco School of Medicine, explains how we should approach these decisions when caring for patients with atopic dermatitis. Dr. Abuabara also spoke on this topic at the 2025 American Academy of Dermatology Annual Meeting.

Guest: Maria Hordinsky, MD, FAAD From clinical research to direct patient care, dermatology tools powered by artificial intelligence (AI) present a new approach to hair loss treatment. Dr. Maria Hordinsky explains how virtual tattoo technology and at-home devices now provide measurable data, improving patient outcomes and allowing dermatologists to personalize treatment with precision. Dr. Hordinsky is the R. W. Goltz Professor and Vice Chair of Research in the Department of Dermatology at the University of Minnesota, and she spoke about this topic at the 2025 American Academy of Dermatology National Meeting.